Literature DB >> 31681986

FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.

Rabia Shahswar1, Gernot Beutel1, Piroska Klement1, Alina Rehberg1, Razif Gabdoulline1, Christian Koenecke1, Dominik Markel1, Hendrik Eggers1, Matthias Eder1, Michael Stadler1, Lothar Hambach1, Steve Ehrlich1, Gudrun Göhring2, Brigitte Schlegelberger2, Elke Dammann1, Marlene Reuter1, Martin Wichmann1, Blerina Neziri1, Arnold Ganser1, Felicitas Thol1, Michael Heuser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31681986     DOI： 10.1111/bjh.16268

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.

Authors:  Ming-Yue Yao; Ya-Fang Wang; Yu Zhao; Li-Jun Ling; Ye He; Jie Wen; Ming-Yue Zheng; Hua-Liang Jiang; Cheng-Ying Xie
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 2.  Emerging agents and regimens for AML.

Authors:  Hongtao Liu
Journal:  J Hematol Oncol       Date:  2021-03-23       Impact factor: 17.388

Review 3.  Treatment of Relapsed Acute Myeloid Leukemia.

Authors:  Felicitas Thol; Arnold Ganser
Journal:  Curr Treat Options Oncol       Date:  2020-06-29

4.  How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.

Authors:  Abhishek Maiti; Marina Y Konopleva
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

5.  Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells.

Authors:  Lindsey M Ludwig; Katrina M Hawley; David B Banks; Anika T Thomas-Toth; Bruce R Blazar; Megan E McNerney; Joel D Leverson; James L LaBelle
Journal:  Cell Death Dis       Date:  2021-10-27       Impact factor: 8.469

6.  A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).

Authors:  Silvia Park; Daehun Kwag; Tong Yoon Kim; Jong Hyuk Lee; Joon Yeop Lee; Gi June Min; Sung Soo Park; Seung-Ah Yahng; Young-Woo Jeon; Seung-Hwan Shin; Jae-Ho Yoon; Sung-Eun Lee; Byung Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Jong Wook Lee; Hee-Je Kim
Journal:  Ther Adv Hematol       Date:  2022-03-23

Review 7.  Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia.

Authors:  Curtis A Lachowiez; Himachandana Atluri; Courtney D DiNardo
Journal:  Ther Adv Hematol       Date:  2022-04-29

Review 8.  Treatment for Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Felicitas Thol; Michael Heuser
Journal:  Hemasphere       Date:  2021-06-01

9.  Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Curtis A Lachowiez; Koichi Takahashi; Sanam Loghavi; Lianchun Xiao; Tapan Kadia; Naval Daver; Maria Adeoti; Nicholas J Short; Koji Sasaki; Sa Wang; Gautam Borthakur; Ghayas Issa; Abhishek Maiti; Yesid Alvarado; Naveen Pemmaraju; Guillermo Montalban Bravo; Lucia Masarova; Musa Yilmaz; Nitin Jain; Michael Andreeff; Elias Jabbour; Guillermo Garcia-Manero; Steven Kornblau; Farhad Ravandi; Marina Y Konopleva; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 50.717

Review 10.  Increasing Role of Targeted Immunotherapies in the Treatment of AML.

Authors:  Jochen Greiner; Marlies Götz; Verena Wais
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.